INCR: Multiplikator Forward P/S InterCure Ltd

InterCure Ltd. (INCR) minimizes regional risks by diversifying sales between Europe and Israel. The forward P/S valuation history demonstrates the dynamics of capitalization relative to future sales, where the 0.50 mark records this metric. High pharmacy standards and variety patents protect the business from competitors. Growth relies on exclusive contracts with European brands as part of its expansion.

INCR InterCure: Rega forward marang dodolan ing interval 25.09.2023 - 13.11.2026

Rincian metrik lan analitis perusahaan intercure.co (INCR)

- rega saham lan target rega konsensus:

Kutipan saham InterCure|INCR - Rega prakiraan analis

- informasi kapitalisasi pasar:

Kapitalisasi pasar INCR|INCR - Total Nilai Perusahaan

- statistik nilai buku emiten:

Aset Bersih saben Siji Saham InterCure|INCR - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku intercure.co|INCR - Gunggung Aset Perusahaan

- data utang lan likuiditas:

- data bathi bisnis lan rasio investasi:

INCR - Bathi resik perusahaan|Bathi mangsa ngarep InterCure Ltd.|INCR - Rasio rega pasar marang bathi resik|Pangali Forward P/E InterCure|INCR - Rasio P/E diaturake wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan INCR|INCR - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) InterCure|INCR - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan intercure.co|INCR - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep InterCure Ltd.

- statistik dodolan lan pendapatan perusahaan:

INCR - Dodolan perusahaan|Prakiraan pendapatan perusahaan InterCure|INCR - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang prakiraan pendapatan INCR

Ringkesan analisis perusahaan:Canndoc INCR

InterCure Ltd. (INCR) status as a leading Israeli medical cannabis operator with exclusive market access makes the company's cash flows predictable. By analyzing the forward P/S based on forecasts, an investor assesses the ratio of current market capitalization to expected revenue, which helps determine the degree of asset undervaluation or the risk of acquiring a business with declining sales during periods of market volatility.

Analisis pesaing

Indivior - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake COLL (Collegium Pharma)|Cronos - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Canopy Growth Corp.|High Tide Inc. (HITI) - Rasio rega marang prakiraan pendapatan|Aurora Cannabis Inc. - Rega forward marang dodolan|ACHV (Achieve Life Sciences, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Skye Bioscience Inc. (SKYE)|Multiplikator forward rega marang pendapatan ANEB (Anebulo)|Multiplikator Forward P/S nutriband.com (NTRB)|Rasio rega marang prakiraan pendapatan Nasus Pharma NSRX|Rega forward marang dodolan IGC|MIRA Pharma - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Flora Growth Corp|IMCC (imcannabis.com) - Multiplikator forward rega marang pendapatan|Adial Pharmaceuticals, Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Artelo Biosciences Inc.|Rasio rega marang prakiraan pendapatan ENSC|Multiplikator forward rega marang pendapatan TTNP (Titan Pharmaceuticals)|Rasio rega marang pendapatan sing dikarepake GNLN|Multiplikator Forward P/S INM (InMed Pharma)|AKAN: Kapitalisasi marang prakiraan pendapatan|ENVB: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Bright Green BGXX|HPCO: Multiplikator Forward P/S